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Summary
A series of novel boronic acid derivatives containing
either a pyrimidine or purine base was synthesized.
The preparation involved the condensation of 4-bro-
mobutyl boronic acid with the appropriate base.
These acyclic nucleosides were designed as poten-
tial antiviral agents especially targeting the human
immunodeficiency virus. Two analogues, 6-chloro-9-
(4-dihydroxyborylbutyl)purine and 2,6-dichloro-9-(4-
dihydroxyborylbutyl)purine, exhibited ECso values of
7.7l!M and O.99l!M, respectively, in an HIV-1 syncytial
plaque reduction assay.
Key-words: antiviral; boronic acid; HIV-1; nucleoside
analogues.
Introduction
A large number and variety of nucleoside analogues have
been synthesized as potential antiviral and antitumour
agents. Some of these compounds are currently in clinical
trials, and others are now being used as chemotherapeu-
tic agents. In general, nucleoside analogues have been
designed as antimetabolites through isosteric substitution
or through modification of the sugar moiety. The former
strategy led to compounds such as 5-iodo-2'-deoxyuri-
dine and 5-fluorouracil, while the latter modification
resulted in the discovery of azidothymidine (AZT) and
cytosine arabinoside. Furthermore, the design of aciclovir
as an acyclic analogue of guanosine, (Schaeffer et al.,
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1978) and its success as an antiherpes agent, have led to
the preparation of a variety of other acyclic analogues as
potential antiviral agents (Harden et al., 1987; Vanden-
driessche et al., 1992; Barnard et al., 1993).
Accordingly, the synthesis of a series of acyclic nucleo-
sides containing the boronic acid functionality as potential
antiviral agents was embarked upon. The studies were
also extended to investigate the potential antitumour
activity of these compounds and, thus, demonstrate the
versatility of the boronic acid moiety. This series of com-
pounds will serve as a model for further structure-activity
relationship (SAR) studies.
Interest in the boronic acid group stems from the fact
that this functionality has been incorporated into many
diverse structures, which has resulted in a range of bio-
logical activities. For example, compounds having
inhibitory activity against serine proteases (Philip and
Bender 1971), chromatin bound protease (Carter et al.,
1977), and dihydroorotase (Kinder et al., 1990) have
been prepared. In addition, boronic acid derivatives have
inhibited cell replication (Goz et al., 1986). Other investi-
gators (Schinazi and Prusoff 1985) have introduced the
boronic acid functionality into the 5- and 6-positions of
pyrimidine as potential antiviral and antitumour agents.
Furthermore, boron-containing compounds have been
designed as candidates for boron neutron capture ther-
apy (Lesnikowski et al., 1993).
Further rationale for the incorporation of boronic acid
into nucleoside analogues is the close relationship of
boron and carbon (Schinazi and Prusoff 1985). The two
hydroxy groups of a boronic acid may behave as alcoholic
hydroxy groups and be preferentially phosphorylated by




The first step in the synthesis of the candidate boronic
acid derivatives is the preparation of 4-bromobutyl
boronic acid (1). This was accomplished according to the
procedure of Brown et al. (1971). 4-Bromo-1-butene was
reacted with an excess of catecholborane under nitrogen.
After removal of the unreacted catecholborane under vac-
uum, water was added to decompose the 2-(4-bro-
mobutyl)-1,3,2-benzodioxaborole and give the desired
product (1) in 78% yield (Fig. 1). 4-Bromobutyl boronic
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acid (1) was then reacted with the appropriate pyrimidine
or purine base utilizing the procedures of Lee et al.,
(1977) and Harden et al., (1987). Thus, thymine was first
reacted with potassium carbonate, after which 4-bro-
mobutyl boronic acid was added to give 1-(4-dihydroxy-
borylbutyl)thymine (2) in 44% yield (Fig. 2). In the
synthesis of 6-chloro-9-(4-dihydroxyborylbutyl)purine (3),
sodium hydride was reacted with 6-chloropurine and the
resultant anion was then reacted with 1 to give the
desired product (3) in 51% yield (Fig. 3). As with the other
purine bases, the N9-isomer was the desired and major
product, and was purified by silica gel chromatography.
With the exception of 6-chloropurine, all other purine
bases were reacted with K2COS by a procedure analo-
gous to that used for compound 2 and depicted in Fig. 2.
In this manner, the 2-amino-6-chloropurine analogue 4
was prepared in a 56% yield. Compound 5, 9-(4-
dihydroxyborylbutyl)guanine, was synthesized in an 81%
yield by refluxing compound 4 in 2N HCI then neutralizing
the acidic reaction mixture (Harden et al., 1987) (Fig. 4).
The latter procedure was also used in the synthesis of
compound 6, 9-(4-dihydroxyborylbutyl)hypoxanthine from
compound 3 (82% yield). The 2,6-dichloro analogue 7 of
compound 3 was prepared in a 48% yield in the
same manner described for compound 2. Compound
8, 6-chloro-9-[4-(1,3-propyldioxaborylbutyl)]purine was
obtained in a 74% yield by reacting 1,3-propanediol with
compound 3 (Goralski et al., 1987) (Fig. 5).
Conformational analysis
Systematic conformational searches of 5 and aciclovir
were performed with Sybyl 6.0 by using new molecular
mechanics force field parameters for the boronic acid
moiety (Chen et al., 1994). Since there are five rotatable
bonds in each side chain, both of these compounds are
very flexible conformationally. There are 10 conforma-
tions that have very similar potential energy for both
compounds; the difference is within 1 kcal mole' . Thus,
at 24 DC, all of these conformations are easily accessible.
The systematic searches indicated that the potential
energy surfaces for both compounds were very similar.
The lowest potential energy conformations for both
aciclovir and 5 were further geometry optimized by
using the AMi semi-empirical method. The resulting
geometries are shown in Fig. 6.
Antiviral and other activities
The boronic acid derivatives (2-8) were screened for their
cell cytotoxicity and anti-HIV-1 activity by utilizing sH-TdR
incorporation into total DNA and an HIV plaque reduction
assay (Kucera et al., 1990). In this series, only two com-
pounds (3 and 7) showed appreciable in-vitro activity. The
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IC5 0 and EC5 0 values of 3 for cytotoxicity and anti-HIV
activity were 43 and 7.7 J.lM, respectively, while those of 7
were 4.9 and 0.99 J.lM, respectively (Table 1). Com-
pounds 2, 4, 5, 6 and 8 had no detectable toxicity or anti-
HIV activity. In addition, the two most potent compounds
in this series (3 and 7), were screened against the SV-28
tumour cell line (Crumpton et al., 1988). These com- .
pounds (3 and 7) had IC5 0 values of 60 J.lM and 4 J.lM,
respectively, in this assay.
The boronic acid derivative 5, a close conformational
analogue of aciclovir, was tested for anti-herpes activity in
a plaque reduction assay using Vero cells (Bastow et al.,
1983). Its EC50 value was 110 J.lM. As compound 5 was
not growth inhibitory at concentrations up to 200 J.lM
against Vero cells, it exhibited selective but weak anti-
herpes activity.
Viral thymidine kinase (TK)
TK+ (ATCC CRL1802) and TK- (LM cells) are two trans-
formed cell lines that lack cellular thymidine kinase
activity. However, the former has been stably transfected
with the herpes simplex virus thymidine kinase, while the
latter has not. These cell lines were used in order to try to
determine whether either of the hydroxy groups of the
boronic acid functionality in 5 is phosphorylated in intact
cells by thymidine kinase. Aciclovir was included in the
assay as a positive control, and it showed distinctly differ-
ent potencies in the two cell lines. The IC5 0 values of
aciclovir against the LM TK+ and the LM TK- cells were
4.4 J.lM and 220 J.lM, respectively. Compound 5 did not
show cytotoxicity against either cell line at concentrations
up to 150 J.lM.
Discussion
A series of novel compounds (2-8) was designed as
antiviral agents especially targeting the human immuno-
deficiency virus. These analogues contain either a pyrimi-
dine ring system as in 2 or a purine ring system as in 3-8
to which is attached a four carbon chain bearing a boronic
acid functionality.
Compound 2 contains thymine, the same pyrimidine
base found in AZT and 2',3'-didehydro-2',3'-dideo-
xythymidine (d4T), but, unlike AZT and d4T, has an
acyclic side chain. This compound (2) exhibited moderate
anti-HIV-1 activity (Table 1).
Among the purine series (3-8), only compounds 3 and
7 showed appreciable activity against HIV-1, while com-
pounds 4-6 and 8 were inactive (Table 1). The rationale
for the synthesis of 3 was based on its facile conversion to
the hypoxanthine analogue (6) and its decreased polarity
compared with analogues 4-6. Thus, the lack of activity of
the latter compounds may be due either to their polar
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Fig. 5. Synthesis of 6-chloro-9-[4-(1 ,3-
propyldioxaborylbutyl)]purine (8).
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Fig. 6. Global minimum conformations of aciclovir (left) and compound 5 (right).
Structure A Structure B Structure C
Table 1. Cytotoxicity and antiviral activity of
compounds (2-8).
ICso for CEM·SS cell sc., for anti-HIV
Cmpd Structure R, R2 R3 toxicity assay plaque reduction assay
2 A B(OHh no inhibition @ 100 J.IM 82J.1M
3 B B(OHh CI H 43±31.1 J.IM 7.7±1.5J.1M
4 B B(OHh CI NH2 no inhibition @ 100 J.IM no activity @ 100 J.IM
5 C B(OHh NH2 no inhibition @ 100 J.IM no activity @ 100 J.IM
6 C B(OHh H no inhibition @ 100 J.IM no activity @ 100 J.IM
7 B B(OHh CI C1 4.9±2.2J.1M 0.99 ± 0.01 J.IM
8 B '0 CI H no inhibition @ 100 J.IM no activity @ 100 J.IM
To measure cytotoxicity, serial concentrations of test compound were added to exponentially
growing CEM-SS cells. After 48 hrs incubation, the cells were pulse labeled with [H3] TdR for 6 hrs to
measure total DNA synthesis in treated and untreated cell cultures and calculate the ICso as
previously described (Kucera et al., 1990). The IC50 value for AZT, the control antiviral compound,
was 5.1 ± 3.0 J.IM as previously reported (Piantadosi et al., 1991).
To measure anti-HIV-1 activity, CEM-SS cell monolayers were infected with HIV-1 and overlaid with
RPMI-1640 medium containing serial concentrations of test compound. After 5 days incubation, the
numbers of HIV-1 syncytial plaques in treated and untreated cell monolayers were counted to
calculate the ECso as previously described (Kucera et al., 1990). The ECso value for AZT, the control
antiviral compound, was 0.004 ± 0.002 J.IM as previously reported (Piantadosi et al., 1991).
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character or to structural features that may interfere with
interaction with a putative target site. If Iipophilicity is a
factor in the increased anti-HIV activity of 3, a further
increase in lipophilicity might result in improvement of
activity. Accordingly, two strategies were devised to
improve on the lipophilic character of 3. One involved the
introduction of an additional chloro group into the purine
ring system as in compound 7; the other involved the
conversion of 3 to its prod rug 8, where the boronic acid
functionality was converted to its 1,3-propyldioxaboryl
derivative.
Compound 7, 2,6-dichloro-9-(4-dihydroxyborylbutyl)-
purine, exhibited more potent anti-HIV activity and
increased cytotoxicity compared with the rnono-chloro
analogue 3. However, the prodrug 8 lost activity, which
suggests that the borate ester functionality may not be
easily hydrolysed intracellularly, and that the boronic acid
functionality is essential for activity.
Since compound 5 is a close conformational analogue
of aciclovir, as determined by conformational analyses
with Sybyl (Fig. 6), it was of interest to determine whether
either of the hydroxy groups of the boronic acid function-
ality in 5 could be phosphorylated by TK as is the hydroxy
group of aciclovir. The ICso of aciclovir in LM TK+ cells
was lower than its ICso in LM TK- cells as expected (see
results); however, compound 5 showed no cytotoxicity
against either cell line at concentrations up to 150 J.lM.
Thus, it was not possible to ascertain if phosphorylation of
5 was required for cytotoxicity. Several possibilities could
account for these data. Compound 5 may not be a sub-
strate for herpes TK but is a substrate for a cellular TK,
since 5 did have some cytotoxicity for SV-28 cells
(ICso = 86 J.lM), which have a cellular TK. The weak activ-
ity of 5 also may be due to poor penetration into the cell
rather than an inability to act as a substrate for herpes TK.
Finally, the boronic acid derivatives may not require TK
for activation. The boronic acid derivatives could be simi-
lar to acyclic nucleoside phosphonates; where the latter
compounds, acting as analogues of nucleoside
monophosphates, bypass the phosphorylation step by TK
(De Clercq, 1995).
Further modifications to maximize activity and reduce
toxicity are in progress.
Materials and Experimental Procedures: Chemistry
Melting points were recorded on a Thomas Hoover melting
point apparatus and are uncorrected. 1H NMR spectra were
obtained using a Bruker AC-300 spectrometer. Elemental
analyses were performed by Atlantic Microlab Inc., Norcross,
GA. Some boronic acid analogues did not give a correct
elemental analysis even though they were pure by NMRand by
TLC in different systems. These compounds were analysed by
using electrospray mass spectroscopy (ESMS). Purity was
also ascertained by high pressure liquid chromatography
(HPLC) with a C18silica column (WhatmanC1851lM particles)
and a linear gradient of15 mM triethylammonium phosphate
(TEAP) (pH 3) to 100% CH3CN. Absorbance of eluent was
monitored at 260 nm. Thin layer chromatography (TLC) was
pertormed on 1x3 inch fluorescent precoated Whatman silica
gel 60 TLC plates. The TLC plates were visualized by UV light,
iodine vapor, or charring following sulphuric acid spray. Silica
gel (70-230 mesh) from Fisher Scientific was used for column
chromatography. Reagents were purchased from Aldrich
Chemical Co., Inc. Solvents, including CH3CN, dimethylfor-
mamide (DMF), CH2CI2,and tetrahydrofuran (THF), were dried
by placement over molecular sieves (4 A) for 2 weeks before
use.
4-Bromobutyl boronic acid 1
4-Bromo-1-butene (5.4 g, 40 mmol) was added to catecholbo-
rane (5.76 g, 48 mmol). The reaction mixture was stirred under
nitrogen and heated to 95°C for 4 h. The unreacted starting
material was distilled under high vacuum.(1 mm Hg) at room
temperature. Water (70 ml) was added to the slightly yellow liq-
uid residue and stirred for 2 h. The white solid was filtered and
recrystallized from CHCI3 . Crystals (5.6 g, 78% yield) were
obtained, which were used directly in the next step. mp
81-83°C; 1HNMR (DMSO-ds) s0.63 (t, 2H, BCH2), 1.40-1.52
(m, 2H, BCH2CH2 ) , 1.61-1.85 (m, 2H, CH2CH2Br), 3.53 (t, 2H,
CH2CH2Br),7.45 [s, 2H, B-(OHM
1-(4-Dihydroxyborylbutyl)thymine 2
Potassiumcarbonate (0.6 g, 4.4 mmol) was added to a solution
of thymine (0.56 g, 4.4 mmol) in DMF (15 ml) and stirred for 30
min. To this reactionmixture, 4-bromobutyl boronic acid (0.4 g,
2.2 mmol) dissolved in DMF (5 ml) was added dropwise, and
stirring was continuedfor 2 days at roomtemperature.After the
K2C03 was filtered, the DMF was evaporated under high vac-
uum. The residue was purified on a silica gel column eluting
with a discontinuous gradient of CHCI3/MeOH (95:5, 85:15).
The appropriate TLC-homogenous fractions were pooled and
evaporated to give 0.22 g (44% yield) of pure product. mp
130-132 °C; 1H NMR (DMSO-ds) Ii 0.62 (t, 2H, BCH2),
1.22-1.35 (m, 2H, BCH2CH2), 1.42-1.60 (m, 2H, CH2CH2N),
1.75 (s, 3H, CH3-C5 thymine), 3.58 (t, 2H, CH2CH2N), 7.42 [s,
2H, B-(OHl2], 7.50 (s, 1H, H-C6 thymine), 11.15 (s, 1H, NH
thymine). Anal. (C9H1S04N2B) calcd. C 47.82, H 6.69, N 12.40;
found C 47.71, H 6.72, N 12.35.
6-Chloro-9-(4-dihydroxyborylbutyl)purine 3
Sodium hydride (0.22 g, 7.2 mmol) was added to 6-chloro-
purine (0.93 g, 6.0 mmol) in DMF (20 ml) and stirred for 10 min.
4-Bromobutyl boronic acid (1.1 g, 6.0 mmol) in DMF (5 ml) was
added to the reaction mixture and stirred at room temperature
for 16 h. After the removal of DMF under high vacuum, the
residue was purified by column chromatography (CHCI3/MeOH
discontinuous gradient 95:5,9:1) to yield 0.78 g (51% yield) of
pure product. mp 135-138°C; 1H NMR (DMSO-ds) s 0.62 (t,
2H, BCH2), 1.22-1.35 (rn, 2H, BCH2CH2), 1.78-1.91 (m, 2H,
CH2CH2N),4.29 (t, 2H, CH2CH2N),7.41 [s, 2H, B-(OH)2J. 8.69
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(s, 1H, H-C8 purine), 8.81 (s, 1H, H-C2 purine). Anal.
(CgH1202N4BCI) calcd. C 42.47, H 4.75, N 22.02; found C
42.48, H 4.80, N 22.06.
2-Amino-6-chloro-9-(4-dihydroxyborylbutyl)purine 4
This analogue was synthesized in a similar manner as com-
pound 2 with 2-amino-6-chloropurine (1.36 g, 8 mmol), 4-bro-
mobutyl boronic acid (1.45 g, 8 mmol), and K2C03 (1.66 g,
12 mmol) in DMF (20 mL). Wgt, 1.2 g, 56% Yield mp
154-156°C; 1H NMR (DMSO-d6) 0 0.62 (t, 2H, BCH2),
1.20-1.32 (m, 2H, BCH2CH2), 1.68-1.77 (m, 2H, CH2CH2N),
4.04 (t, 2H, CH2CH2N), 6.89 (s, 2H, NH2-C2 purine), 7.41 [s,
2H, B-(OHbJ, 8.11 (s, 1H, H-C8 purine). ESMS calcd. for
C9H1302N5BC1270.09 [MHt, found 270.10.
9-(4-Dihydroxyborylbutyl)guanine 5
Compound 4 (0.5 g, 1.85 mmol) was added to aqueous HCI
(5 ml, 2N), and the reaction mixture was heated to reflux for
5 h. After cooling to room temperature, aqueous NaOH (10%)
was added to neutralize the reaction mixture to pH 7. Water
was evaporated under high vacuum, and MeOH was added to
the residue to remove the unreacted starting material. The
remaining solid was washed with water (3x20 ml) then stirred
in water overnight. After filtration, the product was air dried for 2
days. Wt. 0.38 g, 81% Yield. mp 202-205°C; 1H NMR (DMSO-
d6) 0 0.62 (t, 2H, BCH2), 1.20-1.32 (m, 2H, BCH2CH2),
1.62-1.75 (m, 2H, CH2CH2N), 3.93 (t, 2H, CH2CH2N), 6.42 (s,
2H, NH2-C2 guanine), 7.43 [s, 2H, B-(OHbJ, 7.70 (s, 1H, H-C8
guanine), 10.50 (s, 1H, H-N3 guanine). ESMS calcd. for
C9H1403N5B 252.12 [MHt, found 252.10.
9-(4-Dihydroxyborylbutyl)hypoxanthine 6
This analogue was synthesized from compound 3 (88 mg,
0.35 mmol) in a manner analogous to that of compound 5. Wt.
67 mg, 82% Yield. mp 182-184°C; 1H NMR (DMSO-d6) 00.62
(t, 2H, BCH2), 1.22-1.35 (m, 2H, BCH2CH2), 1.70-1.82 (m, 2H,
CH2CH2N), 4.11 (t, 2H, CH2CH2N), 7.39 [s, 2H, B-(OHl2], 8.02
(s, 1H, H-C8 purine), 8.07 (s, 1H, H-C2 purine), 12.25 (s, 1H,
H-N3 purine). ESMS calcd. for C9H1303N4B 236.11 [MHt,
found 236.10.
2,6-Dichloro-9-(4-dihydroxyborylbutyl)purine 7
This analogue was synthesized in a similar manner as outlined
for compound 2 using 2,6-dichloropurine (0.25 g, 1.30 mmol),
4-bromobutyl boronic acid (0.24 g, 1.30 mmol), and K2C03
(0.27 g, 1.98 mmol). Wt. 180 mg, 48% Yield. mp 121-124°C;
1H NMR (DMSO-d6) 00.61 (t, 2H, BCH2), 1.25-1.35 (m, 2H,
BCH2CH2), 1.75-1.85 (m, 2H, CH2CH2N), 4.23 (t, 2H,
CH2CH2N),7.41 [s, 2H, B-(OHl2], 8.75 (s, 1H, H-C8 purine)
ESMS calcd. for CgH1102N4BC12288.93 [MHt, found 289.10.
6-Chloro-9-[4-(1,3-propyldioxaborylbutyl)Jpurine 8
Compound 3 (70 mg, 0.28 mmol) and 1,3-propanediol (22 mg,
0.28 mmol) were dissolved in THF (10 ml) and stirred at room
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temperatur~ overnight. The Solvent was evaporated with a
stream of nitrogen, and the crude product dissolved in a mix-
ture of hexanes and Et20 (95:5). Undissolved solid was dis-
~arded, and pure product (60 mg) was obtained after evapora-
tion of solvent. Wt. 60 mg, 74% Yield. mp 85-87 °C; 1H NMR
(DMSO-d6) 00.62 (t, 2H, BCH2), 1.22-1.35 (m, 2H, BCH2CH2),
1.80-1.90 (rn, 4H, CH2CH2N, OCH2CH2CH20), 3.82-3.95 (m
4H, OCH2CH2CH20), 4.29 (t, 2H, CH2CH2N), 8.69 (s, 1H, H:
C8 purine), 8.81 (s, 1H, H-C2 purine). ESMS calcd. for
C12H1602N4BC1295.10 [MHt, found 295.10.
Materials and Experimental Procedures: Virology
Virus syncytial plaque assay and effective
concentration5 0 (EC5 0) determinations.
A monolayer of CEM-SS cells (T-Iymphocytes)was prepared by
dispensing 50 000 cells per 50 III of RPMI-1640 medium without
serum to each poly-L-Iysine treated well in a 96-well plate. The
cell monolayer formed after 30 min incubation at 37°C was
inoculated with 30-60 plaque forming units of HIV-1 diluted in
RPMI-1640 growth medium. After 90 min of virus adsorption,
the infected cell monolayers were overlaid with 100 III growth
medium supplemented with serial log or 0.5 log dilutions of test
compound. The highest concentration of test compound was
always 2-fold or more below the IC50 for cell toxicity. All plates
were incubated at 37°C in a humidified atmosphere containing
5% CO2and 95% air. After 3 days incubation, a second overlay
of growth medium supplemented with test or control compound
was added and incubation at 37 °C was continued {or an addi-
tional 2 days (total of 5 days). Plaques were counted with the
aid of a 1OX gridded ocular lens and light microscope. The EC50
for anti-HIV-1 activity was calculated from computer program
analysis of the antiviral data. If the EC50 for control compounds
was not within 30% of expected values, the assay was consid-
ered invalid and repeated.
Cytotoxicity assay with the SV-28 tumour eel/line
Preliminary biological screening for antitumour activity was
done with the SV-28 cell line. SV-28 cells are baby hamster
kidney cells transformed by the oncogenic simian virus SV--40.
Cells were grown in flasks with 25 ern" growth area in MEM
medium with 5% foetal calf serum. Immediately before use,
2 mM of glutamine was added to the medium. The pH of the
medium was adjusted from slightly basic to slightly acidic by
adding 0.8% (v/v) of 2N HCI. Cells were transferred by washing
with phosphate buffered saline (PBS) and incubated in 0.02%
EDTA in PBS for 3 min to remove the cells from the flask sur-
face. An appropriate number of cells were added to fresh
medium such that the seeding density was 3x103 cells crn".
After ~24 h, the test compound was added at different concen-
trations (10, 20, 50 IlM), and cells were incubated for another
48 h to allow three doublings according to control cells. At the
end of 48 h, cells were washed with 5 ml of PBS and incubated
with 2 ml of 0.02% EDTA. The cells were loosened by tapping
the flask and then were transferred to a test tube with 0.5 ml of
5 mM CaCI2 in 0.9% saline. The cells were counted with a
haemocytometer. Each compound was tested at least two
times on separate occasions, and reproducible results were
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obtained. The ICso value is the concentration of the test com-
pound that reduced the cell count to 50% compared with the
control culture. For compounds showing cytotoxicity, the
experiments were repeated three times to determine the stan-
dard deviation.
Anti-herpes plaque reduction assay
Confluent monolayers of Vero cells in 9.6 ern" plastic wells
were inoculated with HSV-1 (KOS) in 0.5 ml of RPMI-1640
medium supplemented with 5% calf serum. After 30 min of
adsorption at 37 DC, the medium was replaced with a drug
overlay, which contained 2.5 ml RPMI-1640, 0.8% car-
boxymethycellulose, and 0.5% calf serum with test compounds
at various concentrations (10, 20, 50, 100 11M). Each concen-
tration was done in triplicate. After a 2 day incubation, the cells
were fixed and stained with trypan blue. The number of
plaques were counted, and the concentration that reduced the
plaque count by 50% relative to untreated control was deter-
mined as the ECso value. The ECso value for aciclovir in the
assay system was 1.5 11M as reported previously (Bastow et
al., 1983). Aciclovir at 50 11M, used as the positive control in the
experiment, completely eliminated HSV plaque formation.
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